ISHLT2024: Industry Symposia - Friday
12 April, 2024 11:45 a.m. to 12:45 p.m. CEST
Crossing Bridges: Extending Access to LVAD Therapy
South Hall 1
Abbott
Crossing Bridges: Extending Access to LVAD Therapy
An engaging discussion to investigate the life-saving impact of increasing access to LVAD therapy utilizing a patient-centric approach. Together we can help more people bridge to feeling better and living longer.
Program
Bridging the Divide: Increasing LVAD Consideration for Females
Maryam Alqaseer, MD, King Fahad Specialist Hospital, Dammam, Saudi Arabia
Bridge to Bridge: Preconditioning Patients for Long-Term Support
Evgenij Potapov, MD, PhD, German Heart Institute, Berlin, Germany
Extending Bridges: Applying Elevate Data to Increase Therapy Acceptance
Jens Garbade, MD, PhD, Klinikum Links der Weser, Bremen, Germany
Little Bridges, Big Impression: Utilizing Lvad Therapy in Smaller Sized People
Bart Meyns, MD, PhD, UZ Leuven University Hospital, Leuven, Belgium
Reimagined Clinical Standards: Transformative Innovations in Organ Preservation
South Hall 2
Paragonix
Reimagined Clinical Standards: Transformative Innovations in Organ Preservation
Primary Core Therapy: Lung | Primary Practice Area: Cardiothoracic Surgery
In this comprehensive examination, we delve into the profound impact of cutting-edge preservation methodologies on the field of cardiothoracic surgery. Unveiling the significant advancements and their far-reaching consequences, this presentation provides an in-depth exploration of the transformative effects that advanced preservation techniques have introduced to the realm of cardiothoracic surgical procedures
Program
Hidden Chambers: Exploring the Mechanism of Action of the Paragonix SherpaPak Cardiac Transport System
Jon Kobashigawa, MD, Cedars-Sinai Smidt Heart Insitute and Comprehensive Transplant Center, Los Angeles, CA USA
Controlled Hypothermic Storage for Lung Preservation: Leaving the Ice Age Behind
Laurens Ceulemans, MD, PhD, University Hospitals Leuven, Leuven, Belgium
Stay Cool Under Pressure: Novel Hypothermic and Active Pressure Control for Donor Lungs
Jasleen Kukreja, MD, MPH, University of California San Francisco, San Francisco, CA USA
The Modern Role of ECP in Heart and Lung Transplantation: From Treatment to Prevention
North Hall
Therakos/Mallinckrodt
The Modern Role of ECP in Heart and Lung Transplantation: From Treatment to Prevention
Primary Core Therapy: Lung | Primary Practice Area: Pulmonology
Moderator
Christian Benden, MD, MBA, FCCP, University of Zürich, Zurich, Switzerland
Program
ECP in SOT: From Early Beginnings to Present Times
Christian Benden, MD, MBA, FCCP, University of Zürich, Zurich, Switzerland
ECP after Lung Transplantation / ECP after Heart Transplantation: Clinical Practice - Benefits and limitations
Markus Barten, University Heart & Vascular Center Hamburg, Germany
Andrew Fisher, FRCP, PhD,
Newcastle University, Newcastle upon Tyne, United Kingdom
Changing the Paradigm of Heart Preservation with Hypothermic Oxygenated Perfusion - New HOPE for Hearts
Panorama Hall
XVIVO
Changing the Paradigm of Heart Preservation with Hypothermic Oxygenated Perfusion - New HOPE for Hearts
Primary Core Therapy: Heart | Primary Practice Area: Cardiothoracic Surgery
Heart transplantation procedures have been evolving since the first heart transplant was performed in 1967. Over the years, scientific and clinical advancements have been made, but limitations such as time, distance, and the availability of donor hearts have been constant constraints. Now, there is new hope for hearts. Hypothermic oxygenated perfusion of hearts has accumulated experience across three continents and eleven countries. Listen to experts present groundbreaking clinical results and share their experiences.
Moderators
Danny Ramzy, MD, PhD, FACC, FRCSC, FACS, UT Health Houston / Memorial Hermann Health System, Houston, TX USA
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
Program
Welcome
Christoffer Rosenblad, MSc, BSc, XVIVO, Mölndal, Sweden
Results from the European NIHP2019 Trial: A Randomized, Controlled, Open-Label, Multi-Center Clinical Trial of Non-Ischemic Preservation Using Hypothermic Oxygenated Perfusion of the Donor Heart In Heart Transplantation
Filip Rega, MD, PhD, University Hospital Leuven, Leuven, Belgium
Cardiac HOPE, the Saint Vincent’s Hospital, Sydney Experience as an Early Adopter
Paul Jansz, MD, BMed, PhD, FRACS, St. Vincent's Hospital, Sydney, NSW Australia
PRESERVE Heart Trial: A Prospective, Multi-Center, Single-Arm, Open-Label Study of Hearts Transplanted after Non-Ischemic Heart Preservation from Extended Donors. The Initial US Experience.
Jacob Schroder, MD, Duke University Medical Center, Durham, NC USA